Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Triamcinolone acetonide injectable suspension - Alcon

Drug Profile

Triamcinolone acetonide injectable suspension - Alcon

Alternative Names: Triesence

Latest Information Update: 29 Jun 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alcon
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Eye disorders; Ocular inflammation

Most Recent Events

  • 26 Jun 2016 Novartis Pharmaceuticals and The Chinese University of Hong Kong plan a prospective clinical trial for Wet age-related macular degeneration (Combination therapy) in China (Intravitreous) (ChiCTR-ICR15006619)
  • 20 Apr 2015 No recent reports on development identified - Registered for Eye disorders (Diagnosis) in Germany, Belgium, Finland, France, Greece, Italy, Luxembourg, Netherlands, Spain, Sweden and United Kingdom (Intraocular)
  • 08 Oct 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top